Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

@article{Brufsky2007ZoledronicAI,
  title={Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.},
  author={Adam M. Brufsky and W. Graydon Harker and Joseph Thaddeus Beck and Robert Carroll and Elizabeth Tan-chiu and Christopher Seidler and John A. Hohneker and Leo V Lacerna and Stephanie Petrone and Edith A. Perez},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 7},
  pages={829-36}
}
PURPOSE Treatment with aromatase inhibitors decreases bone mineral density (BMD) and may increase the risk of fractures in postmenopausal women with early-stage breast cancer. The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss. PATIENTS AND METHODS Patients receiving adjuvant letrozole were randomly assigned to receive either upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months). The delayed group received zoledronic acid when… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

Adjuvant aromatase inhibitor therapy: outcomes and safety.

Cancer treatment reviews • 2010
View 4 Excerpts
Highly Influenced

Breast Cancer Chemoprevention: Old and New Approaches

Journal of biomedicine & biotechnology • 2012
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…